Products & Services · Total revenues
Nplate — Total revenues
Amgen Nplate — Total revenues decreased by 95.2% to $412M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 94.9%, from $8.15B to $412M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2019
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing clinical adoption or expanded patient access, while a decrease may signal increased competition from biosimilars or newer therapeutic alternatives.
Detailed definition
This metric represents the total gross sales generated from the Nplate product line, a therapeutic agent used for the tr...
Peer comparison
Comparable to specialized therapeutic product revenue lines at other large-cap biotechnology firms, often benchmarked against market share in niche hematology or immunology segments.
Metric ID:
amgn_segment_nplate_total_revenuesHistorical Data
40 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $245M | $6.71B | $273M | $6.85B | $282M | $6.24B | $266M | $6.59B | $284M | $6.65B | $288M | $6.84B | $459M | $6.11B | $362M | $6.99B | $310M | $6.9B | $419M | $8.2B | $386M | $7.45B | $317M | $8.39B | $346M | $8.5B | $456M | $9.09B | $337M | $8.15B | $313M | $9.18B | $369M | $9.56B | $457M | $9.87B | $385M | $8.62B | $412M |
| QoQ Change | — | -96.2% | >999% | -95.9% | >999% | -95.9% | >999% | -95.7% | >999% | -95.7% | >999% | -95.7% | >999% | -93.3% | >999% | -94.1% | >999% | -95.6% | >999% | -93.9% | >999% | -95.3% | >999% | -95.7% | >999% | -95.9% | >999% | -94.6% | >999% | -96.3% | >999% | -96.2% | >999% | -96.0% | >999% | -95.2% | >999% | -96.1% | >999% | -95.2% |
| YoY Change | — | — | — | — | — | — | — | — | +1.0% | -95.6% | -0.8% | -95.7% | -0.1% | -93.3% | -2.1% | -94.2% | +5.9% | -95.3% | +3.8% | -93.7% | +19.8% | -94.4% | +22.0% | -94.8% | +20.1% | -95.0% | +23.2% | -93.4% | +10.9% | -95.9% | +9.4% | -95.8% | +9.4% | -95.6% | +12.4% | -94.6% | +8.6% | -95.8% | +5.8% | -94.9% |
Range$245M – $9.87B
CAGR-24.7%
Avg YoY Growth-42.8%
Median YoY Growth-47.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's nplate — total revenues?
- Amgen (AMGN) reported nplate — total revenues of $412M in Q1 2026.
- How has Amgen's nplate — total revenues changed year-over-year?
- Amgen's nplate — total revenues decreased by 94.9% year-over-year, from $8.15B to $412M.
- What does nplate — total revenues mean?
- The total revenue generated from sales of the Nplate therapeutic product.